Saturday, November 2, 2024

EXUMA Biotech Announces Participation in the In Vivo Engineering of Therapeutic Cells Summit

EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene therapies for liquid and solid tumors, announced that Dr. Sid Kerkar, the company’s Vice President of Oncology, Research and Development, will participate in the In Vivo Engineering of Therapeutic Cells Summit organized by Hanson Wade on July 12-14, 2022 in Boston.

Also Read: Northwest Biotherapeutics Announces Filing of Application for License for Commercial Manufacturing at Sawston

“We are encouraged by the preclinical findings with EXUMA‘s novel in vivo GCAR technology, which has the potential to overcome many of the barriers surrounding current ex vivo CAR therapies. Our mission is centered on creating highly effective, safe, and durable treatments while reducing manufacturing complexity and costs, and increasing the speed and quality of delivery for the next generation of cell and gene therapies for cancer patients,” said Sid Kerkar, M.D., VP Oncology, R&D.

EXUMA Biotech is a clinical-stage biotechnology company pioneering the discovery and development of novel cell and gene therapies for the treatment of solid and hematological malignancies. The company is leveraging a global R&D footprint to advance product candidates designed to have reduced cost and complexity with safety, efficacy and scalability differentiated from existing cell therapies. EXUMA Biotech is headquartered in West Palm Beach. For more information visit exumabio.com and connect with us on LinkedIn and Twitter.

Subscribe Now

    Hot Topics